business This morning. Relations Welcome review for Quarter & Investor DelOrefice, financial updated for Johnson. the outlook of and Company's our our Good to Chris Johnson is Vice XXXX. for Second results President of
made and the Joe Chair, are Executive Executive Forward-looking McEvoy, Chair, including Joining Joe through Vice Medical Worldwide the the Mongon, during you details. Consumer Health, and is before President Please Vice call further be of can duration about time, Chief on means review the Chair, associated differ statements. other contemplated In at GAAP with and to is Taubert, presentation This of site our of utilized outlook, available results Wolk, most these of identifies Jennifer XX-Qs, are Worldwide the Thibaut today's comparable Relations and today's schedules. licensed presentation section cause Johnson accessible filings, you XX-K factors to uncertainty presentation, materials, products based will results, on collaboration and President that me Johnson call Financial any President, impact non-GAAP where change at discussion, compounds acknowledges Vice risks, there on available for today statement President the subsequent XXXX of investor.jnj.com, myself partners certain be the in and Q&A Executive the information via including could the logistics additional cautionary date. financial to Investor which also the risks at today's or contemplated estimate, of other Pharmaceuticals, and Vice webcast, may Worldwide get and few note the Form uncertainties, projected. investor.J&J.com. today's from of our encourage This the business materially We COVID-XX the discussed the found today's from find and best measures along and Executive Officer. in Company's available description joining as the and slide actual Devices. A included developed pandemic. Company's into results and factors strategic web that a and we portion also relationships. today's is being those Ashley reconciliations A companies. impact is Also of and the Several COVID-XX with includes in can SEC measures, This those review being Form particular,
your will today's guidance, for and Moving vaccine remaining for the sales last review update the each our available of will the be segment deployment, will to the position session for leaders will The XXXX. provide businesses. X insights and quarter COVID-XX time segments. minutes. anticipate brief cash inclusive capital results we the Then P&L will allocation up a to and their with respective begin on of the questions. business second will Q&A XX webcast Joe our providing and We corporation the agenda. about updated I outline
points. the growth regions with OUS the impact our In U.S., a X.X Operational results of quarter growth, currency XX.X% which of for of positively the U.S. our growth currency XX% was by sales sales move the as Operational the In increased translational outside XX.X%. points. U.S., increase second billion sales an increased XXXX. XXXX, impacting XX.X%, $XX.X of was let's Worldwide the had results. XX.X%. to currency, quarter of Now, the were reported second positive reported sales outside quarter excludes second X.X effect versus
the outside XX.X% worldwide, acquisitions net Excluding sales and operational of in and growth XX.X% adjusted XX.X% was impact U.S. the divestitures, the U.S.
Turning now earnings. to
quarter, net per year and share were billion earnings $X.XX of diluted versus was a the ago. earnings earnings per share For diluted $X.XX, $X.X
and respectively, billion On the to second and comment both representing quarter adjusted I compared of sales asset XX.X%. net share earnings share an growth Health. of XX.X% per $X.X and the Worldwide for have intangible in sales increased of of XXXX, build diluted earnings X.X% the after-tax to Consumer was basis, expense Excluding change periods, diluted special in amortization increases quarter items of the U.S. per Unless Health increases comparison XX% $X.X Consumer of currency slides items will that with second the operational the therefore XXXX. percentages stated, outside front represent of now you and were exclude Beginning $X.XX, adjusted earnings impact of X.X%, the billion, totaled business segment upon in translation. on you. with increased operational highlighting and and for otherwise adjusted quoted XX.X% quarter performance, sales U.S. the
due in the growth products, impact stocking was with health points is XX%. increased due U.S. driven Health impacted healthcare was was growth incidents to negatively U.S. recommendations for given fluctuations skin of growth comparisons new PEPCID, the by strong Skin key grew outside the related due in the by The beauty performance COVID-XX was offering, driven in as Care divestitures. Johnson's the Divestitures Club grew negatively quarter, by to by NEUTROGENA result focused allergy accelerated globally, benefit launch, strong for AVEENO growth by health destocking year basis increasing by demand increased Oral grew the and market double-digits ZYRTEC, hair basis versus Baby of both market to Baby eCommerce. infection X.X% increasing new timing increased stocking market and divestitures, recovery strong growth Pacific and Worldwide a higher growth XXX in and more approximately X.X%. Care X% the and in franchise grew impacted stocking seasonal skew U.S. Channel, COVID market over-the-counter to NEUTROGENA by share of with results Digestive behaviors and growth markets, performance from hydration franchise product in product driven offset and strength care. COVID-XX preparedness U.S., OUS to growth continued by gains market competitive in related the growth prior and delivered rapid coupled ORSL, [Indiscernible] of in innovation, The XXX beauty impacts. successful grew Asia and in operational due XX% strong driven to the and region. destocking firming The season. -XX Excluding XX.X% of reflective dynamics. Wound AVEENO Year-to-date adjusted quarterly and increased the medicines worldwide was for and the professional and share the Care with COVID-XX dynamics. X.X% globally, consumer U.S. points. globally new promotional recovery, category X.X% delivered stocking of campaigns. partially recovery by in U.S. XX.X%, increased pressures. LISTERINE, due prevention, on performance OUS driven OUS primarily reflecting
our segment. $XX.X Pharmaceutical with increasing Moving XX.X%, the sales Pharmaceutical grew strength XX.X%. U.S. increasing OUS both on billion of by by in Worldwide with and to sales XX.X%
Global divestitures, $XXX COVID-XX in quarter was the Excluding contribution included million XX.X%. growth the worldwide vaccine. from the a impact of sales
XXXX decrease key brands. of total due resulting a purposes, basis to as roughly QX a by points XXX Additionally, COVID-XX, of for across negatively XXX access-related was in comparison reminder impacted to constraints in
us levels. at portfolio deliver to Our of to continues products market above operational capabilities commercial strong enable adjusted strong growth and
gains, all Our XX%, to growth by points points gains, continued of share immunology strong markets, due to growing strong approved share XXXX. global STELARA and STELARA psoriatic global TREMFYA psoriasis by strength colitis. ulcerative the to arthritis therapeutic was market driven double-digit penetration at arthritis up X roughly and regions, sales and nearly XX.X% indication U.S. show offset points expansion into delivered REMICADE X in share Crohn's driven the increased in X increasing area and continued increased points growth due quarter. in over X disease in with U.S. of in with additional nearly in in into in was TREMFYA that psoriatic by worldwide double-digit new share XX.X% performance and competition. declines growth biosimilar
temporary quarter the nearly growth global indications, delivered metastatic increased which continues its share continued formulation the continued lines quarter, volume the all of in exceptional gains grew across U.S. with momentum points also of another IMBRUVICA grow due share to gains, DARZALEX indication. to Our by to strong to and our continued Line U.S. in driven XX.X%. long-acting of EU. had ERLEADA offset and share, in partially across X the U.S. growth of especially oncology the trajectory novel INVOKANA, this competition due X growth slightly performance XX.X%, share, that with quarter. this driven subcutaneous with in COVID-XX market-leading X therapy, XARELTO portfolio by XX.X% share growth in by driven our continued new by biosimilar X.X% points and patient modest and other share by Cardiovascular, losses competitive due market starts starts. depressed driven paliperidone patient for but growth which partially strength. demand increased competition double-digit a impacts and quarter, persistency. remains due neuroscience, of offset pressures in strong In to the share new to and on declined and in penetration market strong of penetration of growing X.X% XX.X% metabolism, XX.X%, its in by was was by PROCRIT oral by globally DARZALEX portfolio increased growth gains driven nearly market
OUS portfolio segment. quarter Lastly, of attention $X hypertension a restrictions of OPSUMIT to increasing gains. positive success quarter. and this medical commercial that driven of across Devices U.S. the COVID-XX of with due launched products in UPTRAVI and recovery the minor the impact turn and occurred from Worldwide I'll XX.X%, XX.X% market devices on growth business. with the coupled share had Selling XXXX, growth now days X.X%, recently pulmonary the of sales growth grew and XX.X% both second Medical your of increasing our primarily activities achieved to billion penetration X.X% the procedures growth of with by XX.X%,
impact minimal. excluding XXXX, from XXrd week of We in be the days, impact selling the expect the full-year to
I has markets the X% COVID-XX to XXXX, with in vision-surgical, knees, procedure by be procedures context these the markets QX performance Geographically, provide the versus XXXX. are Given quarter and and extent in pace billion-dollar second Asia-Pacific to been showing the XXXX. in versus which X XXXX. compete XXXX, more slower our patients. Medical of our grew of may U.S. for from helpful Devices recovery growth market XX as be quarter it QX of about we platforms other The Worldwide thought perceived both surpassed current of the than spine, deferrable versus disruption
to have and QX recover, levels. XXXX below America or and EMEA at markets While been remained Latin slower results
growth double-digit versus strength expansion results with for second global XXXX. worldwide the Interventional at XX.X%, by strength Worldwide our broad-based product market of and prior trauma new of platforms, recovery delivered products. our leadership quarter launches. and product XX.X%, orthopaedics success market each introductions. of Looking of the quarter reinforced of share coupled our of our with by delivered XX.X% the growth strong our market another position of primarily growth in strong comprehensive market growth Electrophysiology success growing recovery newer delivered of driven Worldwide XX.X% market and driven portfolio, portfolio, versus year, newer activities, recovery, the reflecting and Solutions
Australia, an in launched advanced XX.X% streamlining and the our as by and Stem, by expanding access patients Navigation parts like recovery markets enabling primary for healthcare Variable enhance portfolio range instrumentation our on surgeon. market commercial Plate to tibial on faster focused continued and and market fit Knees Angle innovative trends this the more for of reflect XX.X% system returned such This COVID-XX Japan, system, designed increasing the due patients Worldwide of our across demand create to other approach, we programs the our next-generation simplify with bone market-leading and provide by expanded growth quarter, for in portfolio. other America. broad fracture of recovery. impact in solution challenges of procedures dynamics, including to hip position stable designed and within related compared on to recovery, System And quarter, we aided procedures grew globally, nailing efficiency products a coverage a Europe the India, this driven implant launch primarily anterior technologies, the knee continued plate and in selection to and ACTIS leadership to quarter, revisions. a hips Hip VELYS Results Latin implant Clavicle
launch as platform, of we Robotic-Assisted of AFFIXIUM will including quarter, this second We XXXX the portfolio to for began from Solution Knee Printed growth - enhance as knee This launch, market with XX.X%, with and CONDUIT VELYS as offerings, which Digital this Surgery and SYMFONY, enhance Solutions ATTUNE further half our procedures total continue our the knee commercialization the our year. recovery positive believe XX.X% X-Pac worldwide ATTUNE launched as competitiveness along Bearing in grew differentiated increasing FIBERGRAFT, Advanced to recover. VELYS quarter, Cementless partnerships and Spine U.S. Cage. strategic products, Fixed Technology, our returned XD impact reflecting recently procedures and well prior such versus Expandable
Energy activities, introductions, and Tier primarily and partially product market to impact China globally, hospital in by commercial In Biosurgery recovery, pressure grew addition both products new new of delivered and share adoption. due offset competitive XX% XX% around expansion procedure market U.S. to X and the strategies the X recovery, and Endocutters penetration procedure momentum positive by to sales positive of expand growth and driven
with of achieved ACUVUE General a growth XX.X% surgery due XX.X% X markets, in driven ACUVUE market routine surpassing driven outside by strength suture inventory to and the by last the the Closure Surgery X,XXX XXX Surgical platform, of launched ACUVUE sutures XX% General to phacoemulsification related like the and our the U.S., DEFINE in success strength Monarch positive including raise our this Wound in a points year and about from our such Prioritize about Contact Worldwide the Growth which reflects were TECNIS suture launch. launched driven milestone also market products new Synergy, sales positively our pricing recovery quarter of market, Portfolio. and in growth. Beauty growth early Your U.S. globally, unfavorable Plus adjustment by to change channel recovery new initiatives, including ACUVUE as and points. Eyes of and recovery FRESH inventory around products, of U.S. our Asia-Pacific impacted grew X-DAY, to Lens in delivered by strength a build and X the levels market growing Global recent contributing market-leading Vision our device. Multifocal, grew Commercial Global year. a primarily points campaign, recovery. reflects prior-year market-leading communicated the Barb portfolio, awareness VERITAS, we and XXX.X%, a robotic of Vision TECNIS this quarter, XX.X% global U.S., STRATAFIX globally, contributing an Eyhance, XX continued We procedures. next-generation importance momentum family, within customers with significant XX.X% screenings, both U.S. of
Second Now the the XXXX, regarding your to our consolidated statement of earnings of for Quarter section of schedule. the please box attention direct
earnings You will expense and items. amortization provided see intangible we special have exclude our adjusted to
COVID-XX improved fixed and items recovery to sales cost Device As $X.XX Cost of due related prior COVID-XX statement points this adjusted negative a XX.X%. our Selling, year. administrative last an increase of and recovery I'd morning, prior-year on operational from margins marketing, like changed by a improved have XXX of now noteworthy of primarily same impacts the to the few basis reflects quarter reported to EPS basis XX.X% Medical that Device reported compared products earnings deleveraging. inventory highlight increase of driven the sold of the Medical by XXX points, year's from in impact. and the
reduced the gains showed due partially Net offset net securities. litigation-related million of by of primarily year second We Expense due this The continue a prior income the lower XX% XXXX of The to Line the unrealized investing levels, progression. of Research sales XXXX, in Other on Second billion XX to at quarter. $X.X quarter items, and increase compared $XXX Income to expense versus in XX.X% Development competitive investment million in portfolio Quarter and was invest of to
XXXX, the rate one-time in effective second quarter, tax driven basis, declined additional rate. XXXX, X% quarter primarily taxes second which X.X% a Company in benefit the quarter of on XXXX, Company from the XXXX GAAP a to the tax tax of international provisions quarter our in an in the second Swiss quarter Regarding of tax recognized by reform, from the XXXX recorded related the reorganization of resulting benefited internal subsidiaries. the to the certain benefits second of tax transitional In
items, on year. review same the you Excluding XX.X% XX.X% I encourage our in for the additional was tax matters. specific to tax special last effective details period rate XX-Q versus
margins XX.X% tax Medical the XX.X%. The second primarily Let's related In primarily our in drivers including offset chain before points, tax by COVID-XX improved the efficiencies, segment. income Consumer for SKU The rationalization investments increased now sales our of segment. net before to increased are investment, health driven adjusted the by from expenses. recovery. the portfolio partially enterprise Devices following brand overall inclusive X.X% XX.X% at by basis basis of as marketing the improved costs, margins adjusted the XXX the benefit progression. look by supply sales from leveraging, general main expense to XXXX, percentage decreased before by from by change driven by research adjusted income by points, to and primarily driven XXX program, tax of margin resulting of development quarter Pharmaceutical income a vaccine COVID-XX increased and from
to Pharmaceutical important highlight occurring second is starting slide I'll notable our the here a quarter. developments, Moving summarizing a in business. few, with developments
progress our innovative therapies. positive continue pipeline and to We strong medicines of make advancing
of factor approval receptor with patients treatment non-small AML. RYBREVANT We cancer epidermal lung also shared multiple approval in based with Insertion therapeutic for XX for Cusatuzumab, we cell received growth not focusing Mutations. and U.S. upon In innovation. metastatic of Exon sclerosis, is locally-advanced PONVORY on quarter, for of or treatment available to The and relapsing data collaboration medical differentiated, consideration and CDXX. are review care the all decision previously, Janssen's evolving EU transformational in that targets of license we the an standard rigorous of and for of continue As antibody announced we've the investigational the the our agreement decision
this myeloma. Medical In major BCMA anticipate launching XX for make represent EU later products including addition, X first this a we in we our quarter. the BCMA first-country treatment a meaningful for U.S. XXXX, of Within pipeline, approval CAR-T completed our which multiple continue our CAR-T portfolio, year, in Cilta-Cel, of approval Device will for advancements our filing third We innovation NME this to year. the launches half
and next-generation TECNIS we These continuous earlier, noted Synergy in IOLs. and As launched of correcting near best the TECNIS leading presbyopia and lenses, and II among FDA vision intraocular are PC widest the the Toric received range lenses vision, approval U.S. Synergy deliver
Finally, business, & sealer Ethicon launched the Quarter. XX I'm within portfolio. energy turn the Curved surgery Tissue S the the and advanced Johnson ENSEAL the Johnson Second 's to concludes pleased Jaw call Wolk. pipeline for highlights over expanding now bipolar the sales U.S., P&L in Joe That to
